From the biotech interview that I’m transcribing:
We can never say that there’ll be sufficient analytics to declare that one biotech product is equivalent to the other. That’s why they’re called biosimilars and not biogenerics. It’s the stuff you can’t measure that can kill you. Sometimes.
